Clinical trial
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or…
NCT00461045 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00461045 |
|---|---|
| Title | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma |
| Official title | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | MRZ 0.5 mg/m^2 |
| Enrollment | 15 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | Apr 17, 2007 |
| Last update posted | Dec 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: